Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Cetuximab’s Effectiveness and Toxicity in Advanced Cutaneous Squamous Cell Skin Cancer

News

July 12, 2023
PRESS RELEASE: On July 7, 2023, a new research paper was published in Oncotarget, entitled, “Effectiveness and toxicity of cetuximab with concurrent RT in locally advanced cutaneous squamous cell skin cancer: a case series.” continue reading »

Deciphering Progesterone’s Mechanisms of Action in Breast Cancer

News

July 10, 2023
PRESS RELEASE: On July 1, 2023, a new research perspective was published in Oncotarget, entitled, “Deciphering the mechanisms of action of progesterone in breast cancer.” continue reading »

Transformation of Immunosuppressive mtKRAS Tumors Into Immunostimulatory Tumors by Nerofe and Doxorubicin

News

July 5, 2023
PRESS RELEASE: On July 1, 2023, a new research paper was published in Oncotarget, entitled, “Transformation of immunosuppressive mtKRAS tumors into immunostimulatory tumors by Nerofe and Doxorubicin.” continue reading »

ERβ as a Mediator of Estrogen Signaling in Inflammatory Breast Cancer

News

July 3, 2023
PRESS RELEASE: on June 12, 2023, a new editorial paper was published in Oncotarget, entitled, “ERβ as a mediator of estrogen signaling in inflammatory breast cancer.” continue reading »

Novel GEM Model Unveils PLK1’s Role in Tumorigenesis

Oncotarget

June 29, 2023
In a new editorial, researchers discuss a study using their team’s new genetically engineered mouse (GEM) model to assess PLK1 as a driver of oncogenic transformation. continue reading »